scispace - formally typeset
O

Otto C. Boerman

Researcher at Radboud University Nijmegen

Publications -  358
Citations -  17532

Otto C. Boerman is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radioimmunotherapy & In vivo. The author has an hindex of 66, co-authored 355 publications receiving 15882 citations. Previous affiliations of Otto C. Boerman include Radboud University Nijmegen Medical Centre.

Papers
More filters
Journal Article

Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.

TL;DR: It is suggested that the antibodies OV-TL 3 and Ov-TL 16 are suitable tools for clinical radioimmunodetection of ovarian carcinomas.
Journal ArticleDOI

Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study

TL;DR: Patients with T1DM are more tolerant to forearm IR than healthy controls in the authors' experimental model, and the efficacy of ischemic preconditioning to reduce IR-injury was lower in the patients and was even completely abolished during hyperglycemia.
Journal ArticleDOI

Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.

TL;DR: The use of the residualizing radiolabels (88)Y and (177)Lu in combination with a mAb directed against an internalizing antigen resulted in higher uptake and better retention of the radiolabel in the tumor.
Journal ArticleDOI

PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer

TL;DR: The aim of this study was to assess the potential of PD-L1 micro single-photon emission tomography/computed tomography (microSPECT/CT) using radiolabeled PD- L1 antibodies to measure PD- l1 expression in two immunocompetent tumor models and monitor therapy-induced changes in tumor PD-l1 expression.
Journal ArticleDOI

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.

TL;DR: All tracers showed sufficient targeting of αvβ3 integrin expression to allow for tumor detection and selection of the optimal tracer for specific diagnostic applications also depends on tumor-to-blood ratio and uptake in normal tissues; these factors should therefore also be considered.